Heinz Lubenau | Chief Drug Development Officer
NEC OncoImmunity AS

Heinz Lubenau is currently Chief Executive Officer and co-founder of NEC Bio Therapeutics where he is leading the AI-empowered personalized neoantigen drug development which includes the proprietary product NECVAX-NEO1 and the clinical collaboration with Transgene’s MyVac product. He has been serving as Chief Drug Development Officer of NEC OncoImmunity leading the development activities of the therapeutic neoantigen-targeting activities in cancer patients since April 2022. Up to November 2022 he was Chief Executive Officer of VAXIMM which he co-founded in 2008. Since then, Heinz has been responsible for all activities on the most advanced product VXM01 and the pipeline products including the personalized neoantigen approach, based on an oral, bacteria-based DNA vaccination platform. Prior to this, 2003-2008, he was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at the German ratiopharm company BioGeneriX, where he led the development work of the first biosimilar G-CSF Ratiograstim® from preclinical studies through European marketing approval and launch and of the 2nd generation G-CSF Lonquex from project implementation to clinical Phase 2. In 1994 he joined Servier as Junior Project Leader and rose to Clinical Research Manager and Project Director Internal Medicine in 2001. Heinz Lubenau gained his PhD in pharmacy from Johannes-Gutenberg-University, Mainz.